Qure.ai adds new FDA breakthrough device status for qSpot-TB
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
The company will be managing orders and warehouse operations for Little's, Lacto-calamine, Tri-activ, I-feel, Ourdaily, and Sloan's through the Unicommerce platform
The company recently received CEP certificate approval for Losartan Potassium by EDQM
At least one recognised startup in every State and UT; spread across over 80% of districts
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Subscribe To Our Newsletter & Stay Updated